These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2372673)

  • 1. The natural course of low grade, non-metastatic prostatic carcinoma.
    Adolfsson J; Rönström L; Carstensen J; Löwhagen T; Hedlund PO
    Br J Urol; 1990 Jun; 65(6):611-4. PubMed ID: 2372673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deferred treatment in clinically localised prostatic carcinoma.
    Adolfsson J; Carstensen J; Löwhagen T
    Br J Urol; 1992 Feb; 69(2):183-7. PubMed ID: 1537031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate carcinoma--the value of T stage and grade in predicting metastases and prognosis. A cost-effective approach to clinical staging.
    Allen FJ; de Kock ML; de Klerk DP; Heyns CF
    S Afr J Surg; 1991 Mar; 29(1):15-8. PubMed ID: 1905062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The natural course of prostatic carcinoma in relation to initial cytological grade.
    Adolfsson J; Fåhraeus B
    J Urol; 1988 Dec; 140(6):1452-4. PubMed ID: 3193514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of modal deoxyribonucleic acid in low grade, low stage untreated prostate cancer.
    Adolfsson J; Rönström L; Hedlund PO; Löwhagen T; Carstensen J; Tribukait B
    J Urol; 1990 Dec; 144(6):1404-6; discussion 1406-7. PubMed ID: 2231935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour markers as prognostic aids in prostatic carcinoma.
    Lewenhaupt A; Ekman P; Eneroth P; Nilsson B
    Br J Urol; 1990 Aug; 66(2):182-7. PubMed ID: 1697204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA-ploidy as prognostic factor in prostatic carcinoma.
    Haugen OA; Mjølnerød O
    Int J Cancer; 1990 Feb; 45(2):224-8. PubMed ID: 2303288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural history of localised prostatic cancer. A population-based study in 223 untreated patients.
    Johansson JE; Adami HO; Andersson SO; Bergström R; Krusemo UB; Kraaz W
    Lancet; 1989 Apr; 1(8642):799-803. PubMed ID: 2564901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear DNA analysis: the relevance of ploidy, DNA heterogeneity and phases of the cell cycle in 329 patients with prostatic carcinoma. A study on a follow-up of eight years.
    al-Abadi H; Nagel R
    Urol Int; 1990; 45(6):350-5. PubMed ID: 2288053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression and survival in prostatic adenocarcinoma: a comparison of clinical stage, Gleason grade, S-phase fraction and DNA ploidy.
    Vesalainen S; Nordling S; Lipponen P; Talja M; Syrjänen K
    Br J Cancer; 1994 Aug; 70(2):309-14. PubMed ID: 8054280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].
    Arrizabalaga Moreno M; García González JI; Mora Durvan M; Díez Rodríguez JM; Esteban Artiaga R; Navarro Sebastián J; Castro Pita M; Paniagua Andrés P
    Actas Urol Esp; 1997 Sep; 21(8):724-36. PubMed ID: 9412221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic significance of histological grading and pathological staging in carcinoma of the prostate.
    Wilson JW; Morales A; Bruce AW
    J Urol; 1983 Sep; 130(3):481-3. PubMed ID: 6887359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
    Oosterlinck W; Mattelaer J; Casselman J; Van Velthoven R; Derde MP; Kaufman L
    Acta Urol Belg; 1997 Oct; 65(3):63-71. PubMed ID: 9421938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.
    Stege R; Grande M; Carlström K; Tribukait B; Pousette A
    Clin Cancer Res; 2000 Jan; 6(1):160-5. PubMed ID: 10656445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A major solid undifferentiated carcinoma pattern correlates with tumour progression in locally advanced prostatic carcinoma.
    Gaffney EF; O'Sullivan SN; O'Brien A
    Histopathology; 1992 Sep; 21(3):249-55. PubMed ID: 1398521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural course of clinically localized prostate adenocarcinoma in men less than 70 years old.
    Adolfsson J; Carstensen J
    J Urol; 1991 Jul; 146(1):96-8. PubMed ID: 2056609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
    Borgmann V; al-Abadi H; Nagel R
    Am J Clin Oncol; 1988; 11 Suppl 1():S19-28. PubMed ID: 2968759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deferred treatment of low grade stage T3 prostate cancer without distant metastases.
    Adolfsson J
    J Urol; 1993 Feb; 149(2):326-8; discussion 328-9. PubMed ID: 8426412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Multivariate analysis of prognostic factors in patients with prostatic cancer].
    Miyamoto T; Yuasa M; Furukawa A; Tamura M; Kawanishi Y; Numata A; Imagawa A; Kagawa S
    Hinyokika Kiyo; 1991 Dec; 37(12):1663-8. PubMed ID: 1785390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stage D1 prostate carcinoma. The histologic appearance of nodal metastases and its relationship to survival.
    Brawn P; Kuhl D; Johnson C; Pandya P; McCord R
    Cancer; 1990 Feb; 65(3):538-43. PubMed ID: 2297644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.